RXi Pharmaceuticals has exclusively licensed to second-generation RNAi technology from Invitrogen for designated target genes in all human therapeutic categories.
Invitrogen’s patent applications that are part of this agreement cover Stealth™ and other technologies related to enhanced configurations of chemically modified double-stranded RNA.
